Wei Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wei Li has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Guoyang He
Department of Pathology, Xinxiang Medical University, Xinxiang, China
3 shared publications - Dan Zhang
Department of Pathology, Xinxiang Medical University, Xinxiang 453003, China
1 shared publication Huifang Zhu
Department of Pathology, Xinxiang Medical University, Xinxiang, China
1 shared publication- Jingyu Zhang
Department of Pathology, Xinxiang Medical University, Xinxiang 453003, China
1 shared publication Junle Li
Department of Pathology, Xinxiang Medical University, Xinxiang, China
1 shared publicationKe Ma
Department of Pathology, Xinxiang Medical University, Xinxiang, China
1 shared publication
Latest Publications
- 10 January 2026
- Published by Springer Nature in Apoptosis
- Vol. 31 (1) , 20
Autophagy regulation of pyroptosis and ferroptosis: a new strategy for colorectal cancer treatment
Colorectal cancer (CRC), a highly prevalent malignant neoplasm worldwide, poses significant challenges in clinical management due to resistance to radiotherapy and chemotherapy. Notably, chemoresistance in CRC is frequently linked to elevated autophagy levels, prompting extensive exploration of combination therapies that integrate chemotherapeutic agents with autophagy modulators, including both inducers and inhibitors. Moreover, the induction of programmed cell death (PCD) in tumor cells has the potential to improve the therapeutic efficacy of anti-tumor treatments and address key challenges related to drug resistance. Pyroptosis and ferroptosis, two distinct types of PCD, have emerged as potential tumor-suppressive mechanisms owing to their unique molecular characteristics. Increasing evidence supports functional crosstalk between these two processes. Autophagy exerts complex regulatory effects on pyroptosis and ferroptosis through multiple functional subtypes. Growing evidence indicates that various pharmacological agents, small molecules, nanocarrier-based delivery systems, and specific autophagic pathways can selectively induce pyroptosis or ferroptosis. Moreover, combining autophagy modulators with standard radiotherapeutic or chemotherapeutic regimens holds significant promise for enhancing treatment outcomes and restore drug sensitivity in CRC. This review systematically summarizes the molecular mechanisms underlying pyroptosis and ferroptosis along with their roles in CRC pathogenesis, elucidates the central regulatory function of autophagy, discusses innovative strategies leveraging autophagy-mediated activation of pyroptosis and ferroptosis, and evaluates the synergistic potential inherent of integrating autophagy modulation with established treatment modalities. Finally, current challenges pertaining to mechanistic research and clinical translation are critically assessed to provide a robust theoretical foundation for future advances in CRC therapeutics.
- 10 January 2026
- Published by Springer Nature in Apoptosis
- Vol. 31 (1) , 20
Autophagy regulation of pyroptosis and ferroptosis: a new strategy for colorectal cancer treatment
Colorectal cancer (CRC), a highly prevalent malignant neoplasm worldwide, poses significant challenges in clinical management due to resistance to radiotherapy and chemotherapy. Notably, chemoresistance in CRC is frequently linked to elevated autophagy levels, prompting extensive exploration of combination therapies that integrate chemotherapeutic agents with autophagy modulators, including both inducers and inhibitors. Moreover, the induction of programmed cell death (PCD) in tumor cells has the potential to improve the therapeutic efficacy of anti-tumor treatments and address key challenges related to drug resistance. Pyroptosis and ferroptosis, two distinct types of PCD, have emerged as potential tumor-suppressive mechanisms owing to their unique molecular characteristics. Increasing evidence supports functional crosstalk between these two processes. Autophagy exerts complex regulatory effects on pyroptosis and ferroptosis through multiple functional subtypes. Growing evidence indicates that various pharmacological agents, small molecules, nanocarrier-based delivery systems, and specific autophagic pathways can selectively induce pyroptosis or ferroptosis. Moreover, combining autophagy modulators with standard radiotherapeutic or chemotherapeutic regimens holds significant promise for enhancing treatment outcomes and restore drug sensitivity in CRC. This review systematically summarizes the molecular mechanisms underlying pyroptosis and ferroptosis along with their roles in CRC pathogenesis, elucidates the central regulatory function of autophagy, discusses innovative strategies leveraging autophagy-mediated activation of pyroptosis and ferroptosis, and evaluates the synergistic potential inherent of integrating autophagy modulation with established treatment modalities. Finally, current challenges pertaining to mechanistic research and clinical translation are critically assessed to provide a robust theoretical foundation for future advances in CRC therapeutics.
- Open Access
The noncausal association between a loss-of-function CLCN2 variant and childhood absence epilepsy
- Open Access
The Causal Relationship between PCSK9 Inhibitors and Malignant Tumors: A Mendelian Randomization Study Based on Drug Targeting
Objective: This study explores the potential causal association between proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors and tumor development using Mendelian randomization (MR) based on drug targets. Methods: Instrumental variables within ±100 kb of the PCSK9 gene locus, impacting low-density lipoprotein cholesterol (LDL-C), were utilized for MR analysis. Coronary heart disease (CHD) served as a positive control to validate the causal relationship between PCSK9 inhibitors and various cancers. We employed reverse MR to address the reverse causation concerns. Data from positive controls and tumors were sourced from OpenGWAS. Results: MR analysis suggested a negative causal relationship between PCSK9 inhibitors and both breast and lung cancers (95%CIBreast cancer 0.81~0.99, p = 2.25 × 10−2; 95%CILung cancer 0.65~0.94, p = 2.55 × 10−3). In contrast, a positive causal link was observed with gastric, hepatic, and oral pharyngeal cancers and cervical intraepithelial neoplasia (95%CIGastric cancer 1.14~1.75, p = 1.88 × 10−2; 95%CIHepatic cancer 1.46~2.53, p = 1.16 × 10−2; 95%CIOral cavity and pharyngeal cancer 4.49~6.33, p = 3.36 × 10−4; 95%CICarcinoma in situ of cervix uteri 4.56~7.12, p = 6.91 × 10−3), without heterogeneity or pleiotropy (p > 0.05). Sensitivity analyses confirmed these findings. The results of MR of drug targets suggested no causal relationship between PCSK9 inhibitors and bladder cancer, thyroid cancer, pancreatic cancer, colorectal cancer, malignant neoplasms of the kidney (except for renal pelvis tumors), malignant neoplasms of the brain, and malignant neoplasms of the esophagus (p > 0.05). Reverse MR helped mitigate reverse causation effects. Conclusions: The study indicates a divergent causal relationship of PCSK9 inhibitors with certain cancers. While negatively associated with breast and lung cancers, a positive causal association was observed with gastric, hepatic, oral cavity, and pharyngeal cancers and cervical carcinoma in situ. No causal links were found with bladder, thyroid, pancreatic, colorectal, certain kidney, brain, and esophageal cancers.
Open AccessThe Causal Relationship between PCSK9 Inhibitors and Malignant Tumors: A Mendelian Randomization Study Based on Drug Targeting
Objective: This study explores the potential causal association between proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors and tumor development using Mendelian randomization (MR) based on drug targets. Methods: Instrumental variables within ±100 kb of the PCSK9 gene locus, impacting low-density lipoprotein cholesterol (LDL-C), were utilized for MR analysis. Coronary heart disease (CHD) served as a positive control to validate the causal relationship between PCSK9 inhibitors and various cancers. We employed reverse MR to address the reverse causation concerns. Data from positive controls and tumors were sourced from OpenGWAS. Results: MR analysis suggested a negative causal relationship between PCSK9 inhibitors and both breast and lung cancers (95%CIBreast cancer 0.81~0.99, p = 2.25 × 10−2; 95%CILung cancer 0.65~0.94, p = 2.55 × 10−3). In contrast, a positive causal link was observed with gastric, hepatic, and oral pharyngeal cancers and cervical intraepithelial neoplasia (95%CIGastric cancer 1.14~1.75, p = 1.88 × 10−2; 95%CIHepatic cancer 1.46~2.53, p = 1.16 × 10−2; 95%CIOral cavity and pharyngeal cancer 4.49~6.33, p = 3.36 × 10−4; 95%CICarcinoma in situ of cervix uteri 4.56~7.12, p = 6.91 × 10−3), without heterogeneity or pleiotropy (p > 0.05). Sensitivity analyses confirmed these findings. The results of MR of drug targets suggested no causal relationship between PCSK9 inhibitors and bladder cancer, thyroid cancer, pancreatic cancer, colorectal cancer, malignant neoplasms of the kidney (except for renal pelvis tumors), malignant neoplasms of the brain, and malignant neoplasms of the esophagus (p > 0.05). Reverse MR helped mitigate reverse causation effects. Conclusions: The study indicates a divergent causal relationship of PCSK9 inhibitors with certain cancers. While negatively associated with breast and lung cancers, a positive causal association was observed with gastric, hepatic, oral cavity, and pharyngeal cancers and cervical carcinoma in situ. No causal links were found with bladder, thyroid, pancreatic, colorectal, certain kidney, brain, and esophageal cancers.